Insulin Resistance - Pipeline Review, H1 2020

January 2020 | 51 pages | ID: IA118C5E59AEN
Global Markets Direct

Abstracts

Insulin Resistance - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Insulin Resistance - Pipeline Review, H1 2020, provides an overview of the Insulin Resistance (Metabolic Disorders) pipeline landscape.

Insulin resistance (IR) is a condition in which the body's cells become resistant to the effects of insulin. This occurs when insulin levels are sufficiently high over a prolonged period of time causing the body’s own sensitivity to the hormone to be reduced. Symptoms include lethargy, hunger, difficulty concentrating and high blood pressure. Predisposing factors include obesity and hypertension.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Insulin Resistance - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Insulin Resistance (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insulin Resistance (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Insulin Resistance (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Insulin Resistance (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Insulin Resistance (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Insulin Resistance (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Insulin Resistance (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Insulin Resistance (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Insulin Resistance (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Insulin Resistance (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Insulin Resistance - Overview
Insulin Resistance - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Insulin Resistance - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Insulin Resistance - Companies Involved in Therapeutics Development
Alize Pharma III SAS
Exscien Corp
F. Hoffmann-La Roche Ltd
Lixte Biotechnology Holdings Inc
Neurodon LLC
NorthSea Therapeutics BV
Pfizer Inc
Recursion Pharmaceuticals Inc
Symmetry Therapeutics Inc
Insulin Resistance - Drug Profiles
AZP-3404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Insulin Resistance - Dormant Projects
Insulin Resistance - Product Development Milestones
Featured News & Press Releases
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Insulin Resistance, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Insulin Resistance - Pipeline by Alize Pharma III SAS, H1 2020
Insulin Resistance - Pipeline by Exscien Corp, H1 2020
Insulin Resistance - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Insulin Resistance - Pipeline by Lixte Biotechnology Holdings Inc, H1 2020
Insulin Resistance - Pipeline by Neurodon LLC, H1 2020
Insulin Resistance - Pipeline by NorthSea Therapeutics BV, H1 2020
Insulin Resistance - Pipeline by Pfizer Inc, H1 2020
Insulin Resistance - Pipeline by Recursion Pharmaceuticals Inc, H1 2020
Insulin Resistance - Pipeline by Symmetry Therapeutics Inc, H1 2020
Insulin Resistance - Dormant Projects, H1 2020
Insulin Resistance - Dormant Projects, H1 2020 (Contd..1), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Insulin Resistance, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Alize Pharma III SAS
Exscien Corp
F. Hoffmann-La Roche Ltd
Lixte Biotechnology Holdings Inc
Neurodon LLC
NorthSea Therapeutics BV
Pfizer Inc
Recursion Pharmaceuticals Inc
Symmetry Therapeutics Inc